Pfizer completes up to $10 billion acquisition of Metsera
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated